NovAliX will be present at “EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry”
September 1st – 5th 2019
Do not miss the opportunity to discuss with our BD Director and the NovAliX team to learn more about our latest offer and plans.
Contact: Dr. Frank Moffatt
We have also the pleasure to present a the following scientific communication:
“BIOPHYSICS AND STRUCTURAL BIOLOGY FOR THE SOSA APPROACH: DEVELOPMENT OF HASPIN INHIBITORS VIA THE OPTIMIZATION OF THE SIDE ACTIVITY OF PIM1 INHIBITORS”.
Gilbert BEY (1), Pierre-Emmanuel BROUTIN (1), Pascal MULLER (1), Paola CIAPETTI (1), Nathalie WEIDNER (1), Dominique Roecklin (1), Thomas NEUMANN (1), Jan EHLERT (2), Michael KUBBUTAT (2)
1) NovAliX, 850 bd Sébastien Brant F‐67400 Illkirch, France
2) ProQinase, Breisacher Str. 117 D‐79106 Freiburg, Germany
With the aim of testing our drug discovery tool-box to identify therapeutic relevant compounds, PIM1 was selected as target of choice. PIM1 is a serine/threonine kinase involved in leukemia, lymphoma and prostate cancer, but also in pulmonary hypertension. PIM1 has a recognized role in T cell development and has been implicated in the pathogenesis of autoimmunity.
See you in Athens!